MX2024010134A - Sintesis de inhibidores de tirosina quinasa de bruton. - Google Patents

Sintesis de inhibidores de tirosina quinasa de bruton.

Info

Publication number
MX2024010134A
MX2024010134A MX2024010134A MX2024010134A MX2024010134A MX 2024010134 A MX2024010134 A MX 2024010134A MX 2024010134 A MX2024010134 A MX 2024010134A MX 2024010134 A MX2024010134 A MX 2024010134A MX 2024010134 A MX2024010134 A MX 2024010134A
Authority
MX
Mexico
Prior art keywords
bruton
synthesis
tyrosine kinase
kinase inhibitors
formula
Prior art date
Application number
MX2024010134A
Other languages
English (en)
Spanish (es)
Inventor
Edward Cleator
Philippe Fernandes
William Marc Maton
Christos Xiouras
Ngoc Duc Tran
Thomas Joachim Landewald Rammeloo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2024010134A publication Critical patent/MX2024010134A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Health & Medical Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2024010134A 2022-02-18 2023-02-17 Sintesis de inhibidores de tirosina quinasa de bruton. MX2024010134A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GR20220100151 2022-02-18
EP22167032 2022-04-06
EP22178413 2022-06-10
PCT/EP2023/054043 WO2023156599A1 (en) 2022-02-18 2023-02-17 Synthesis of bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2024010134A true MX2024010134A (es) 2024-08-27

Family

ID=85227338

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010134A MX2024010134A (es) 2022-02-18 2023-02-17 Sintesis de inhibidores de tirosina quinasa de bruton.

Country Status (13)

Country Link
US (1) US20250163076A1 (https=)
EP (1) EP4479405A1 (https=)
JP (1) JP2025506671A (https=)
KR (1) KR20240148351A (https=)
AU (1) AU2023221549A1 (https=)
CA (1) CA3252338A1 (https=)
CL (1) CL2024002409A1 (https=)
CO (1) CO2024011229A2 (https=)
IL (1) IL314902A (https=)
JO (1) JOP20240182A1 (https=)
MX (1) MX2024010134A (https=)
PE (1) PE20242069A1 (https=)
WO (1) WO2023156599A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025262118A1 (en) * 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
CA3252338A1 (en) 2023-08-24
KR20240148351A (ko) 2024-10-11
EP4479405A1 (en) 2024-12-25
IL314902A (en) 2024-10-01
PE20242069A1 (es) 2024-10-18
JP2025506671A (ja) 2025-03-13
JOP20240182A1 (ar) 2024-08-14
CO2024011229A2 (es) 2024-08-30
US20250163076A1 (en) 2025-05-22
WO2023156599A1 (en) 2023-08-24
AU2023221549A1 (en) 2024-10-03
CL2024002409A1 (es) 2025-01-03

Similar Documents

Publication Publication Date Title
EA201000113A1 (ru) Пиразольные соединения
CL2024002895A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
WO2021195533A3 (en) Synthesis of modified oligonucleotides with increased stability
PE20220430A1 (es) PROCESO PARA LA SINTESIS DE 4-({2-[(AMINOSULFONIL)AMINO]ETIL}AMINO)-N-(3-BROMO-4-FLUOROFENILl)-N'-HIDROXI-1,2,5-OXADIAZOL-3-CARBOXIMIDAMIDA UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA
EA201070480A1 (ru) Ингибиторы с-fms киназы
EA201991779A3 (ru) Способы получения ингибиторов jak киназ и родственных промежуточных соединений
MX2022013941A (es) Inhibidores de imino sulfanona de enpp1.
EA201070186A1 (ru) Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2024010134A (es) Sintesis de inhibidores de tirosina quinasa de bruton.
CO2025018750A2 (es) Inhibidores de wrn
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
MX2024004690A (es) Un esquema de sintesis y procedimientos para preparar un inhibidor de sik3 y compuestos intermedios del mismo.
MX2025012180A (es) Sintesis de inhibidores de ras
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
DOP2025000212A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
CL2023001018A1 (es) Compuestos inhibidores de autotaxina
MX2025000791A (es) Compuestos terapeuticos, formulaciones y uso de los mismos
MX2025007840A (es) Formas de estado sólido de inhibidores de mnk
DE602006017038D1 (de) Menthancarbonsäureamidderivate mit kühlenden eigenschaften
EA200700179A1 (ru) Производные пиррола, их получение и их применение в терапии
BRPI0519948A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica e método de tratamento de cáncer em um mamìfero
AR132901A1 (es) Inhibidores de wrn
EA200801400A1 (ru) Новые производные индолизина, способ их получения и терапевтические композиции на их основе